Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Lung Neoplasms 4Neoplasms 3Carcinoma 3Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lung Diseases 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Adenocarcinoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1NSCLC 1Mesothelioma, Malignant 1Hemangioendothelioma, Epithelioid 1EGFR-mutated NSCLC (Disorder) 1

Interventions

osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hemangioendothelioma, Epithelioid × osimertinib × Clear all
NCT05228015 2024-11-18

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Ikena Oncology

Phase 1 Terminated
67 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Hemangioendothelioma, Epithelioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡